| Identification | Back Directory | [Name]
D-3263 | [CAS]
947257-66-1 | [Synonyms]
D-3263
D3263,D 3263
D3263;D 3263;D-3263
3-(2-aminoethyl)-5-methoxy-1-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexanecarbonyl]benzimidazol-2-one
3-(2-AMINO-ETHYL)-1(R)-[(2(S)-ISOPROPYL-5(R)-METHYL CYCLOHEXANECARBONYL)]-5-METHOXY-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONE
2H-Benzimidazol-2-one, 3-(2-aminoethyl)-1,3-dihydro-5-methoxy-1-[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]- | [Molecular Formula]
C21H31N3O3 | [MDL Number]
MFCD25976809 | [MOL File]
947257-66-1.mol | [Molecular Weight]
373.49 |
| Chemical Properties | Back Directory | [Boiling point ]
521.8±60.0 °C(Predicted) | [density ]
1.137±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
9.60±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
D-3263 is an agonist of transient receptor potential melastatin member 8 (TRPM8) with potential antineoplastic activity. | [in vivo]
D-3263 (50 or 100 mg/kg/d) alone or with Finasteride (10 mg/kg/d) results in reduction in prostate hyperplasia of rats with evidence of a dose response. The highest dose of the TRPM8 agonist D-3263, given in combination with Finasteride, results in lower prostate weights than the highest dose of D-3263 or Finasteride given alone, suggesting a potential additive effect[1]. | [storage]
Store at -20°C | [References]
[1] David Duncan, et al. PRECLINICAL EVALUATION OF THE TRPM8 ION CHANNEL AGONIST D-3263 FOR BENIGN PROSTATIC HYPERPLASIA. THE JOURNAL OF UROLOGY, Vol. 181, No. 4, Supplement, Tuesday, April 28, 2009 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|